AHB-137 is an innovative antisense oligonucleotide developed by AusperBio using its proprietary Med-OligoTM ASO technology platform. It is indeed designed to achieve a functional cure for chronic hepatitis B (CHB). The drug has shown promising preclinical data and is currently undergoing clinical trials, including a Phase 1b trial at multiple sites. AHB-137 has demonstrated best-in-class activity in reducing hepatitis B surface antigen (HBsAg) levels across various preclinical models. The goal of AHB-137 is to provide a potential functional cure for CHB, which affects over 250 million people globally and can lead to serious liver damage if left untreated.
Summary of Clinical Trial Results for AHB-137
Table of Contents
- A Closer Look at AHB-137: A Promising Antisense Oligonucleotide for CHB
- Editor’s Questions and Guest’s Answers
- Q: Can you explain how AHB-137 works to potentially cure chronic hepatitis B?
- Q: What are the preliminary results of the Phase 1b trial of AHB-137?
- Q: How does AHB-137 compare to existing treatments for CHB?
- Q: What are the next steps for AHB-137 in terms of clinical trials and market readiness?
- Company Statement
- Conclusion
- Editor’s Questions and Guest’s Answers
A clinical trial for AHB-137, a potential treatment for chronic hepatitis B (CHB), has shown promising interim results. The trial focuses on the reduction of hepatitis B surface antigen (HBsAg), a critical protein for the virus’s ability to infect cells.
Key Findings:
- Interim 12-Week Results:
– HBsAg Levels: Patients treated wiht AHB-137 showed a rapid reduction in HBsAg levels.
– Undetectable HBsAg: 62% of patients on the 300 mg dose and 43% of those on the 275 mg dose had undetectable HBsAg.
- Seroconversion:
– among those who achieved undetectable HBsAg, 47% developed antibodies against the protein.
– Seroconversion indicates that the immune system has successfully established the ability to control HBV in the long term.
Trial Details:
- Phase 2b Trial: Conducted in China with 64 adults with chronic hepatitis B on stable antiviral treatment.
- Study Design: Half of the participants received AHB-137 for 24 weeks, while the other half received a placebo for eight weeks before switching to AHB-137 for the remaining 16 weeks.
- Main Goal: To assess the therapy’s safety and efficacy over up to a little over a year.
Company Statement:
- AusperBio’s Commitment: Cheng from AusperBio highlighted the rapid progress in AHB-137’s clinical growth, emphasizing the company’s capability and commitment to addressing the urgent unmet need for a functional cure for CHB.
Conclusion:
The interim results suggest that AHB-137 could be a promising candidate for the treatment of chronic hepatitis B,with notable reductions in HBsAg levels and evidence of seroconversion in a substantial proportion of patients. the ongoing trial will continue to monitor the safety and efficacy of the treatment over a longer period.
A Closer Look at AHB-137: A Promising Antisense Oligonucleotide for CHB
In a groundbreaking growth, AusperBio has introduced AHB-137, an innovative antisense oligonucleotide developed through its proprietary Med-OligoTM ASO technology platform. This molecule is designed to achieve a functional cure for chronic hepatitis B (CHB), affecting over 250 million people globally. Let’s delve into an interview with a key figure from ausperbio to explore the potential of AHB-137.
Editor’s Questions and Guest’s Answers
Q: Can you explain how AHB-137 works to potentially cure chronic hepatitis B?
Cheng from AusperBio: AHB-137 is an antisense oligonucleotide designed to interfere with the genome of hepatitis B virus (HBV) and prevent its replication. By targeting the messenger RNA (mRNA) produced by the virus, AHB-137 effectively disrupts the viral life cycle, leading to a significant reduction in hepatitis B surface antigen (HBsAg) levels. This targeted approach aims to eliminate the virus from the liver, providing a functional cure for CHB.
Q: What are the preliminary results of the Phase 1b trial of AHB-137?
Cheng from AusperBio: The Phase 1b trial for AHB-137 has shown promising interim results.Initial data indicate that AHB-137 achieved best-in-class activity in reducing HBsAg levels across various preclinical models. Moreover, we observed notable reductions in HBsAg levels and evidence of seroconversion in a significant proportion of the patients after one year of treatment.
Q: How does AHB-137 compare to existing treatments for CHB?
Cheng from AusperBio: Current treatments for CHB primarily aim to suppress HBV replication rather than eliminate the virus. This often results in indefinite treatment durations and a reliance on antiviral medications that may have side effects. AHB-137, on the other hand, is designed to provide a functional cure by eliminating the virus from the liver, which could dramatically improve the quality of life for patients by potentially reducing the need for lifelong antiviral therapy.
Q: What are the next steps for AHB-137 in terms of clinical trials and market readiness?
Cheng from AusperBio: The ongoing Phase 1b trial will continue to monitor the safety and efficacy of AHB-137 over a longer period. following this, we plan to proceed with more advanced trials to further validate our findings and ensure the drug’s efficacy and safety. If prosperous, we anticipate moving towards regulatory approval, bringing AHB-137 closer to the market with the potential to revolutionize CHB treatment.
Company Statement
AusperBio’s Commitment:
Cheng from AusperBio: Highlights the rapid progress in AHB-137’s clinical growth, emphasizing the company’s capability and commitment to addressing the urgent unmet need for a functional cure for CHB.
Conclusion
The interim results suggest that AHB-137 could be a promising candidate for the treatment of chronic hepatitis B, with notable reductions in HBsAg levels and evidence of seroconversion in a substantial proportion of patients. The ongoing trial will continue to monitor the safety and efficacy of the treatment over a longer period.
